479PA phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study. (23rd October 2018) - Honda, M; Matsuda, C; Tanaka, C; Kondo, K; Takahashi, T; Kosugi, C; Tokunaga, Y; Takemoto, H; Kim, H M; Sakamoto, J; Oba, K; Mishima, H